Clinical usefulness of gefitinib for non-small-cell lung cancer with a double epidermal growth factor receptor mutation

類似資料

• Tumor volume determines the feasibility of cell‐free DNA sequencing for mutation detection in non‐small cell lung cancer
  著者:: Ohira, Tatsuo, 等
  出版事項: (2016)
• Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer
  著者:: Nakajima, Eiji, 等
  出版事項: (2019)
• Comment on prognostic value of epidermal growth factor receptor mutation subtypes in surgically resected non-small cell lung cancer
  著者:: Kudo, Yujin, 等
  出版事項: (2017)
• Epidermal growth factor receptor mutation subtype has differential effects on adjuvant chemotherapy for resected adenocarcinoma pathological stages II–III
  著者:: Kawaguchi, Yohei, 等
  出版事項: (2019)
• Gefitinib in treatment of metastatic non-small cell lung cancer (NSCLC) with mutated epidermal growth factor receptor (EGFR)
  著者:: Singh, Charu
  出版事項: (2014)